GGrantIndex
← Search

SDZ DJN 608 MONOTHERAPY COMPARED TO GLIBENCLAMIDE MONOTHERAPY B304 E

$0M01FY2000RRNIH

Washington University, Saint Louis MO

Investigators

Linked publications & trials

Abstract

Evaluate the effect of SDZ DJN 608 120mg and 60mg montherapy compared to glibenclamide monotherapy (10mg/day) on glycosylated hemoglobin (HbA) at 24 weeks of double-blind treatment in patients previously treated by diet an sulfonylureas.

View original record on NIH RePORTER →